soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Company profile
Ticker
SNGX
Exchange
Website
CEO
Christopher Schaber
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Enteron Pharmaceuticals, Inc. • Orasomal Technologies Inc. • Soligenix BioPharma Canada Incorporated • Soligenix UK Limited • Soligenix NE B.V. • Soligenix Biopharma HI, Inc. ...
IRS number
411505029
SNGX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
19 Apr 24
424B4
Prospectus supplement with pricing info
19 Apr 24
EFFECT
Notice of effectiveness
17 Apr 24
8-K
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
3 Apr 24
S-1/A
IPO registration (amended)
2 Apr 24
S-1/A
IPO registration (amended)
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
S-1
IPO registration
12 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Dec 23
EFFECT
Notice of effectiveness
18 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.30 mm | 10.30 mm | 10.30 mm | 10.30 mm | 10.30 mm | 10.30 mm |
Cash burn (monthly) | 954.14 k | 547.26 k | 593.02 k | 780.85 k | 895.44 k | 866.92 k |
Cash used (since last report) | 6.38 mm | 3.66 mm | 3.97 mm | 5.22 mm | 5.99 mm | 5.80 mm |
Cash remaining | 3.92 mm | 6.64 mm | 6.33 mm | 5.08 mm | 4.31 mm | 4.50 mm |
Runway (months of cash) | 4.1 | 12.1 | 10.7 | 6.5 | 4.8 | 5.2 |
Institutional ownership, Q2 2023
20.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 5 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 990.43 mm |
Total shares | 2.12 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sabby Management | 814.25 k | $573.07 mm |
Altamont Phamaceutical | 678.34 k | $1.05 mm |
Anson Funds Management | 514.14 k | $361.86 mm |
Vanguard | 26.77 k | $18.84 mm |
First Wilshire Securities Management | 23.33 k | $16.00 k |
Geode Capital Management | 20.92 k | $14.53 mm |
VIRT Virtu Financial | 14.14 k | $10.00 k |
Warberg Asset Management | 10.00 k | $7.04 mm |
Tower Research Capital | 6.89 k | $4.85 mm |
Plante Moran Financial Advisors | 4.78 k | $3.36 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Dec 23 | Zeldis Jerome B | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
15 Dec 23 | Parks Diane L. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
15 Dec 23 | Rubin Robert J. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
15 Dec 23 | Lapointe Anthony Gregg | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
8 Dec 23 | Jonathan L. Guarino | Option Common Stock | Grant | Acquire A | No | No | 0.67 | 90,000 | 60.30 k | 90,000 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
19 Apr 24
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
19 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Apr 24
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
18 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Apr 24
Press releases
Soligenix Announces Pricing of $4.75 Million Public Offering
18 Apr 24
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
15 Apr 24
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
11 Apr 24
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
3 Apr 24
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
15 Mar 24